Literature DB >> 15661894

Dynamic interactions of Fc gamma receptor IIB with filamin-bound SHIP1 amplify filamentous actin-dependent negative regulation of Fc epsilon receptor I signaling.

Renaud Lesourne1, Wolf H Fridman, Marc Daëron.   

Abstract

The engagement of high affinity receptors for IgE (FcepsilonRI) generates both positive and negative signals whose integration determines the intensity of mast cell responses. FcepsilonRI-positive signals are also negatively regulated by low affinity receptors for IgG (FcgammaRIIB). Although the constitutive negative regulation of FcepsilonRI signaling was shown to depend on the submembranous F-actin skeleton, the role of this compartment in FcgammaRIIB-dependent inhibition is unknown. We show in this study that the F-actin skeleton is essential for FcgammaRIIB-dependent negative regulation. It contains SHIP1, the phosphatase responsible for inhibition, which is constitutively associated with the actin-binding protein, filamin-1. After coaggregation, FcgammaRIIB and FcepsilonRI rapidly interact with the F-actin skeleton and engage SHIP1 and filamin-1. Later, filamin-1 and F-actin dissociate from FcR complexes, whereas SHIP1 remains associated with FcgammaRIIB. Based on these results, we propose a dynamic model in which the submembranous F-actin skeleton forms an inhibitory compartment where filamin-1 functions as a donor of SHIP1 for FcgammaRIIB, which concentrate this phosphatase in the vicinity of FcepsilonRI and thereby extinguish activation signals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661894     DOI: 10.4049/jimmunol.174.3.1365

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Fc receptors as adaptive immunoreceptors.

Authors:  Marc Daëron
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

2.  Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells.

Authors:  Wei Zhao; Christopher L Kepley; Penelope A Morel; Lawrence M Okumoto; Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 3.  Mast cells in airway diseases and interstitial lung disease.

Authors:  Glenn Cruse; Peter Bradding
Journal:  Eur J Pharmacol       Date:  2015-05-08       Impact factor: 4.432

4.  Coaggregation of FcepsilonRI with FcgammaRIIB Inhibits Degranulation but Not Induction of Bcl-2 Family Members A1 and Bim in Mast Cells.

Authors:  Maria Ekoff; Christine Möller; Zou Xiang; Gunnar Nilsson
Journal:  Allergy Asthma Clin Immunol       Date:  2006-09-15       Impact factor: 3.406

5.  Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.

Authors:  Grant R Stenton; Lloyd F Mackenzie; Patrick Tam; Jennifer L Cross; Curtis Harwig; Jeffrey Raymond; Judy Toews; Joyce Wu; Nancy Ogden; Thomas MacRury; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

6.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

7.  Mast cells and company.

Authors:  Friederike Jönsson; Marc Daëron
Journal:  Front Immunol       Date:  2012-02-20       Impact factor: 7.561

8.  Activation/Inhibition of mast cells by supra-optimal antigen concentrations.

Authors:  Michael Huber
Journal:  Cell Commun Signal       Date:  2013-01-22       Impact factor: 5.712

Review 9.  Decoding IgE Fc receptors.

Authors:  Ming Zhang; Richard F Murphy; Devendra K Agrawal
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

Review 10.  Phosphoinositide phosphatases in a network of signalling reactions.

Authors:  Daniel Blero; Bernard Payrastre; Stéphane Schurmans; Christophe Erneux
Journal:  Pflugers Arch       Date:  2007-06-29       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.